Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Bedrock Bedrock +20.06%
#4 Cysic Cysic +18.33%
#5 Fabric Protocol Fabric Protocol +13.41%
#6 Nockchain Nockchain +11.94%
#7 Perle Perle +8.19%
#8 stake.link stake.link +8.12%
#9 Arowana Arowana +7.88%
#10 Cap Cap +7.72%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Classement en actions #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Prix de l'action
$0.1
Dernière synchronisation: 2024-06-18
Capitalisation boursière
$1.31M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Pascal Biosciences Inc. (PSCBF)

Catégorie

Healthcare
Ratio P/B pour Pascal Biosciences Inc. (PSCBF)
Ratio P/B au August 2026 TTM : 2.64
Selon les derniers rapports financiers et le cours de l'action de Pascal Biosciences Inc., le ratio cours/valeur comptable actuel (TTM) est 2.64. À la fin de 2022, le ratio P/B était de -1.43.
Historique du ratio P/B pour Pascal Biosciences Inc. de 2019 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) 2.64 127.72%
2023 1.16 -181.08%
2022 -1.43 7,479.37%
2021 -0.02 6,200.00%
2020 0.00 0.00%
2019 0.00 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 137.04%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 140.33%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 37.57%
BE